Literature DB >> 17588749

Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk.

Cassandra L Woodard1, Susan M Keenan, Lucia Gerena, William J Welsh, Jeanne A Geyer, Norman C Waters.   

Abstract

We tested Pfmrk against several naphthalene and isoquinoline sulfonamides previously reported as protein kinase A (PKA) inhibitors. Pfmrk is a Cyclin Dependent protein Kinase (CDK) from Plasmodium falciparum, the causative parasite of the most lethal form of malaria. We find that the isoquinoline sulfonamides are potent inhibitors of Pfmrk and that substitution on the 5 position of the isoquinoline ring greatly influences the degree of potency. Molecular modeling studies suggest that the nitrogen atom in the isoquinoline ring plays a key role in ligand-receptor interactions. Structural analysis suggests that even subtle differences in amino acid composition within the active sites are responsible for conferring specificity of these inhibitors for Pfmrk over PKA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588749     DOI: 10.1016/j.bmcl.2007.06.032

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Leveraging biotech's drug discovery expertise for neglected diseases.

Authors:  Joanna E Lowell; Christopher D Earl
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

2.  Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents.

Authors:  Sandrine Houzé; Nha-Thu Hoang; Olivier Lozach; Jacques Le Bras; Laurent Meijer; Hervé Galons; Luc Demange
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

Review 3.  An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors.

Authors:  Chantalle Moolman; Rencia van der Sluis; Richard M Beteck; Lesetja J Legoabe
Journal:  Molecules       Date:  2020-11-07       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.